US2016287673A1PendingUtilityA1

Compositions and methods for treating corneal epithelial wound

56
Assignee: REGENERX BIOPHARMACEUTICALS INCPriority: Jun 17, 2005Filed: Jun 15, 2016Published: Oct 6, 2016
Est. expiryJun 17, 2025(expired)· nominal 20-yr term from priority
Inventors:David CrockfordAllan L. Goldstein
A61P 43/00A61K 38/2292A61K 47/02A61P 31/00A61P 27/04A61K 9/08A61K 9/14A61P 31/12A61K 9/0048A61K 47/186A61P 27/06A61K 9/10A61P 31/10A61P 31/04A61P 27/02A61P 27/14A61K 38/08A61P 29/00
56
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A composition comprising a peptide agent comprising amino acid sequence LKKTET (SEQ. ID NO.: 1) or Thymosin β4 (Tβ4) can treat a corneal epithelial wound caused by epithelial debridement.

Claims

exact text as granted — not AI-modified
1 . A method of treating a corneal epithelial wound, comprising administering to a subject suffering from a corneal epithelial wound an ophthalmically acceptable composition comprising a peptide agent comprising amino acid sequence LKKTET (SEQ. ID NO.: 1) or Thymosin β4 (Tβ4), wherein the wound is caused by epithelial debridement. 
     
     
         2 . The method of  claim 1 , wherein the epithelial debridement is caused during a surgical procedure or corneal resurfacing procedure. 
     
     
         3 . The method of  claim 2 , wherein the surgical procedure is a laser-assisted in situ keratomileusis (LASIK) surgical procedure or a laser-assisted subepithelial keratomileusis (LASEK) surgical procedure. 
     
     
         4 . The method of  claim 1 , wherein the composition has a pH of about 6.8-8.1. 
     
     
         5 . The method of  claim 1 , wherein the composition has a pH of about 6.8-7.4. 
     
     
         6 . The method of  claim 1  wherein the composition comprises an aqueous medium. 
     
     
         7 . The method of  claim 6 , wherein the peptide agent is present in the aqueous medium at a concentration within a range of about 0.001-1,000 mg/ml. 
     
     
         8 . The method of  claim 7 , wherein the peptide agent is present in the aqueous medium at a concentration within a range of about 0.1-10 mg/ml. 
     
     
         9 . The method of  claim 1 , wherein the composition is administered to the subject at least once per day. 
     
     
         10 . The method of  claim 9 , wherein the composition is administered to the subject two, three, four, five or six times per day. 
     
     
         11 . The method of  claim 1  wherein the peptide agent comprises amino acid sequence LKKTET. 
     
     
         12 . The method of  claim 1 , wherein the peptide agent comprises Tβ4.

Join the waitlist — get patent alerts

Track US2016287673A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.